-+ 0.00%
-+ 0.00%
-+ 0.00%

Future Science & Technology Holdings joins KRW 7 billion Series A for RNA therapy developer

PUBT·11/17/2026 01:19:07
Listen to the news
Future Science & Technology Holdings joins KRW 7 billion Series A for RNA therapy developer
  • Future Science & Technology Holdings participated in anti-aging RNA developer Lifelex Science's KRW 7 billion Series A financing announced on the 13th.
  • Proceeds will fund clinical trial preparations and trials for its lead osteoarthritis RNA treatment, based on a microRNA degradation platform.
  • The treatment is in preclinical development, with clinical trials targeted for the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Future Science & Technology Holdings Co Ltd published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.